FDA Launches Safety Review Of Weight Loss Drug

Law360, New York (November 23, 2009, 5:10 PM EST) -- The U.S. Food and Drug Administration has launched an expedited safety review of sibutramine based on a recent study showing that some patients taking the weight loss drug, which Abbott Laboratories markets as Meridia, have a higher rate of heart attacks, strokes and other cardiovascular events.

The agency is studying the initial data from a six-year study examining the effects of the drug on overweight or obese subjects at risk of a cardiovascular event, the FDA said Friday.

The regulator warned that it has not yet...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.